- The body’s immune system may destroy the melanocytes
- Melanocytes may destroy themselves
- Defective nerve cells may make toxic substances that harm the melanocytes
- Family members with vitiligo or hair turning gray early
- Age: 10 to 30
- Certain autoimmune diseases, most notably thyroid disease
- Areas exposed to the sun: face, hands, arms, upper part of the chest
- Areas around body openings: eyes, nostrils, mouth, navel, genitals
- Body folds: groin, armpits
- Sites of chronic minor injury: knuckles, elbows
- Sites of injury: scrapes, cuts, burns
- Area right around moles
- Repigmentation—replace skin color in patches
- Slowing loss of color
- Decreasing difference between affected and unaffected skin
PUVA (Psoralen plus UVA) and Narrow Band UVB (nbUVB)
- Corticosteroid skin creams—can sometimes slow the loss of color. It may also help return color to small areas. They may also cause thinning of the skin.
- Tacrolimus or pimecrolimus skin creams—can sometimes slow the loss of color. They can help return color to small areas. They may also cause thinning of the skin.
- Skin grafting —done if the condition is not widespread and stable. It may be possible to graft areas of normal pigmentation to the patches.
|Copyright © Nucleus Medical Media, Inc.|
- Protect the depigmented area from the damaging effects of sun exposure
- Prevent increased pigmentation (tanning) of other areas, which will greatly accentuate the vitiligo
National Vitiligo Foundation http://www.vitiligofoundation.org/
American Academy of Dermatology http://www.aad.org/
Canadian Dermatology Association http://www.dermatology.ca/
American Academy of Dermatology website. Available at: http://www.aad.org .
Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society. Guideline for the diagnosis and management of vitiligo. Br J Dermatol . 2008 Nov;159(5):1051-76.
Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol. 2005;44:57-60.
National Institute of Arthritis and Musculoskeletal and Skin Diseases website. Available at: http://www.niams.nih.gov/ .
National Vitiligo Foundation website. Available at: http://www.vitiligofoundation.org/ .
Nicolaidou E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: A review. J Am Acad Dermatol . 2009 Jan 19.
Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med . 2009 Jan 8;360(2):160-9.
- Reviewer: Purvee S. Shah, MD
- Review Date: 09/2012 -
- Update Date: 00/91/2012 -